Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 165 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Liraglutide Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

NCT02863419
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
40
States / cities
Birmingham, Alabama • Los Alamitos, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Jul 24, 2026, 3:15 AM EDT
Completed No phase listed Observational

Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants

NCT02608853
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
9,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 1 Interventional

Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

NCT02650206
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation
Interventions
Victoza (liraglutide) with dietician monitoring, Placebo with dietician monitoring
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 69 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

NCT02235961
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC9204-0530, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

NCT01952145
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
31
States / cities
Fresno, California • Los Alamitos, California • Palm Springs, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 4 Interventional

The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans

NCT02403284
View directory record Official record
Conditions
Insulin Resistance
Interventions
Liraglutide, Sugar Pill
Drug
Lead sponsor
Phoenix VA Health Care System
Federal
Eligibility
40 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

NCT01624259
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
LY2189265, Liraglutide, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Phoenix, Arizona • Chino, California • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 2 Interventional

Study That Tests AD109 in Patients Taking GLP-1 Drugs

NCT06400615
View directory record Official record
Conditions
OSA
Interventions
AD109
Drug
Lead sponsor
Apnimed
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Anniston, Alabama • Jacksonville, Florida • Monroe, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jul 24, 2026, 3:15 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

NCT01206101
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 1 Interventional

Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

NCT02870231
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC9204-0530, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

NCT02518945
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Insulin, Liraglutide, Dapagliflozin placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS

NCT03480022
View directory record Official record
Conditions
Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android
Interventions
Liraglutide Pen Injector [Saxenda], Placebo Liraglutide Pen Injector
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes

NCT02140983
View directory record Official record
Conditions
Insulin Resistance, Dementia
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

NCT02501161
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
44
States / cities
Muscle Shoals, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 1 Interventional Results available

Multiple Ascending Dose Study of AMG 598 in Adults With Obesity

NCT03757130
View directory record Official record
Conditions
Obesity
Interventions
AMG 598, Placebo, Liraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Tustin, California • South Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Jul 24, 2026, 3:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Preoperative Weight Loss for Open Abdominal Wall Reconstruction

NCT05925959
View directory record Official record
Conditions
Abdominal Wall Hernia
Interventions
Preoperative Weight Management Program
Other
Lead sponsor
Benjamin T. Miller
Other
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 4 Interventional Results available

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

NCT05579249
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00518882
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
61
States / cities
Birmingham, Alabama • Goodyear, Arizona • Artesia, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 2 Interventional Results available

Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy

NCT04883346
View directory record Official record
Conditions
Obesity, Status Post Sleeve Gastrectomy
Interventions
Liraglutide
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 20 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Not applicable Interventional Results available

Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes

NCT02777073
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Victoza, Placebo, Dapagliflozin 10mg Tab
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 4 Interventional Results available

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

NCT02014740
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Obesity
Interventions
Liraglutide, Metformin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Jul 24, 2026, 3:15 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes

NCT01722227
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
15 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

NCT03115424
View directory record Official record
Conditions
Obesity
Interventions
Saxenda, Placebos, RYGB
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Jul 24, 2026, 3:15 AM EDT
Completed Phase 4 Interventional Results available

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

NCT01505673
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Liraglutide, Saline
Drug
Lead sponsor
Ildiko Lingvay
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Jul 24, 2026, 3:15 AM EDT